AKER BIOMARINE ASA (AKBM.OL) Fundamental Analysis & Valuation

OSL:AKBM • NO0010886625

Current stock price

100.2 NOK
-2.8 (-2.72%)
Last:

This AKBM.OL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. AKBM.OL Profitability Analysis

1.1 Basic Checks

  • In the past year AKBM has reported negative net income.
  • In the past year AKBM had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: AKBM reported negative net income in multiple years.
  • Each year in the past 5 years AKBM had a positive operating cash flow.
AKBM.OL Yearly Net Income VS EBIT VS OCF VS FCFAKBM.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M 150M

1.2 Ratios

  • With a Return On Assets value of -5.95%, AKBM is not doing good in the industry: 85.71% of the companies in the same industry are doing better.
  • The Return On Equity of AKBM (-15.91%) is worse than 90.48% of its industry peers.
  • The Return On Invested Capital of AKBM (3.18%) is worse than 73.02% of its industry peers.
Industry RankSector Rank
ROA -5.95%
ROE -15.91%
ROIC 3.18%
ROA(3y)13.66%
ROA(5y)8.23%
ROE(3y)30.37%
ROE(5y)18.32%
ROIC(3y)N/A
ROIC(5y)N/A
AKBM.OL Yearly ROA, ROE, ROICAKBM.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80 100

1.3 Margins

  • AKBM has a Operating Margin (5.82%) which is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of AKBM has grown nicely.
  • AKBM has a Gross Margin of 44.84%. This is in the better half of the industry: AKBM outperforms 73.02% of its industry peers.
  • AKBM's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 5.82%
PM (TTM) N/A
GM 44.84%
OM growth 3Y-9.71%
OM growth 5Y19.03%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.69%
GM growth 5Y3.38%
AKBM.OL Yearly Profit, Operating, Gross MarginsAKBM.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. AKBM.OL Health Analysis

2.1 Basic Checks

  • AKBM has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, AKBM has about the same amount of shares outstanding.
  • AKBM has about the same amout of shares outstanding than it did 5 years ago.
  • AKBM has a worse debt/assets ratio than last year.
AKBM.OL Yearly Shares OutstandingAKBM.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
AKBM.OL Yearly Total Debt VS Total AssetsAKBM.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • A Debt/Equity ratio of 1.11 is on the high side and indicates that AKBM has dependencies on debt financing.
  • AKBM's Debt to Equity ratio of 1.11 is on the low side compared to the rest of the industry. AKBM is outperformed by 79.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Altman-Z N/A
ROIC/WACC0.37
WACC8.55%
AKBM.OL Yearly LT Debt VS Equity VS FCFAKBM.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 2.47 indicates that AKBM has no problem at all paying its short term obligations.
  • AKBM has a Current ratio of 2.47. This is amongst the best in the industry. AKBM outperforms 87.30% of its industry peers.
  • AKBM has a Quick Ratio of 1.08. This is a normal value and indicates that AKBM is financially healthy and should not expect problems in meeting its short term obligations.
  • AKBM's Quick ratio of 1.08 is fine compared to the rest of the industry. AKBM outperforms 69.84% of its industry peers.
Industry RankSector Rank
Current Ratio 2.47
Quick Ratio 1.08
AKBM.OL Yearly Current Assets VS Current LiabilitesAKBM.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AKBM.OL Growth Analysis

3.1 Past

  • The earnings per share for AKBM have decreased strongly by -111.62% in the last year.
  • AKBM shows a decrease in Revenue. In the last year, the revenue decreased by -4.68%.
  • AKBM shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.45% yearly.
EPS 1Y (TTM)-111.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.2%
Revenue 1Y (TTM)-4.68%
Revenue growth 3Y-7.68%
Revenue growth 5Y-5.45%
Sales Q2Q%6.15%

3.2 Future

  • Based on estimates for the next years, AKBM will show a very strong growth in Earnings Per Share. The EPS will grow by 114.20% on average per year.
  • The Revenue is expected to grow by 27.17% on average over the next years. This is a very strong growth
EPS Next Y178.44%
EPS Next 2Y114.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.36%
Revenue Next 2Y12.66%
Revenue Next 3Y40.08%
Revenue Next 5Y27.17%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AKBM.OL Yearly Revenue VS EstimatesAKBM.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
AKBM.OL Yearly EPS VS EstimatesAKBM.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 0.1 -0.1 0.2 0.3

More info and screens

Find the best growth stocksShow best growing peers

2

4. AKBM.OL Valuation Analysis

4.1 Price/Earnings Ratio

  • AKBM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • AKBM is valuated quite expensively with a Price/Forward Earnings ratio of 43.49.
  • AKBM's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. AKBM is more expensive than 77.78% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of AKBM to the average of the S&P500 Index (22.42), we can say AKBM is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 43.49
AKBM.OL Price Earnings VS Forward Price EarningsAKBM.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AKBM is valued a bit more expensive than 76.19% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 20.82
AKBM.OL Per share dataAKBM.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • AKBM's earnings are expected to grow with 114.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y114.2%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AKBM.OL Dividend Analysis

5.1 Amount

  • No dividends for AKBM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AKBM.OL Fundamentals: All Metrics, Ratios and Statistics

AKER BIOMARINE ASA

OSL:AKBM (3/23/2026, 9:40:55 AM)

100.2

-2.8 (-2.72%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)02-12
Earnings (Next)04-30
Inst Owners6.04%
Inst Owner ChangeN/A
Ins Owners6.14%
Ins Owner ChangeN/A
Market Cap8.79B
Revenue(TTM)218.10M
Net Income(TTM)-22.90M
Analysts77.78
Price Target96.9 (-3.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend40.63
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-8.21%
Min Revenue beat(2)-10.8%
Max Revenue beat(2)-5.62%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.76%
PT rev (3m)11.76%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 43.49
P/S 4.22
P/FCF N/A
P/OCF 209.24
P/B 6.4
P/tB 34.1
EV/EBITDA 20.82
EPS(TTM)-2.3
EYN/A
EPS(NY)2.3
Fwd EY2.3%
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)0.48
OCFY0.48%
SpS23.74
BVpS15.66
TBVpS2.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.95%
ROE -15.91%
ROCE 4.12%
ROIC 3.18%
ROICexc 3.36%
ROICexgc 5.62%
OM 5.82%
PM (TTM) N/A
GM 44.84%
FCFM N/A
ROA(3y)13.66%
ROA(5y)8.23%
ROE(3y)30.37%
ROE(5y)18.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y21.17%
ROICexgc growth 5Y36.24%
ROICexc growth 3Y11.56%
ROICexc growth 5Y31.47%
OM growth 3Y-9.71%
OM growth 5Y19.03%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.69%
GM growth 5Y3.38%
F-Score3
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Debt/EBITDA 2.98
Cap/Depr 21.87%
Cap/Sales 4.08%
Interest Coverage 0.8
Cash Conversion 8.24%
Profit Quality N/A
Current Ratio 2.47
Quick Ratio 1.08
Altman-Z N/A
F-Score3
WACC8.55%
ROIC/WACC0.37
Cap/Depr(3y)54.82%
Cap/Depr(5y)82.58%
Cap/Sales(3y)10.13%
Cap/Sales(5y)15.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-111.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.2%
EPS Next Y178.44%
EPS Next 2Y114.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.68%
Revenue growth 3Y-7.68%
Revenue growth 5Y-5.45%
Sales Q2Q%6.15%
Revenue Next Year15.36%
Revenue Next 2Y12.66%
Revenue Next 3Y40.08%
Revenue Next 5Y27.17%
EBIT growth 1Y388.64%
EBIT growth 3Y-16.64%
EBIT growth 5Y12.54%
EBIT Next Year270%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.93%
OCF growth 3Y-33.7%
OCF growth 5YN/A

AKER BIOMARINE ASA / AKBM.OL Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AKER BIOMARINE ASA?

ChartMill assigns a fundamental rating of 3 / 10 to AKBM.OL.


Can you provide the valuation status for AKER BIOMARINE ASA?

ChartMill assigns a valuation rating of 2 / 10 to AKER BIOMARINE ASA (AKBM.OL). This can be considered as Overvalued.


Can you provide the profitability details for AKER BIOMARINE ASA?

AKER BIOMARINE ASA (AKBM.OL) has a profitability rating of 3 / 10.


How financially healthy is AKER BIOMARINE ASA?

The financial health rating of AKER BIOMARINE ASA (AKBM.OL) is 3 / 10.


What is the earnings growth outlook for AKER BIOMARINE ASA?

The Earnings per Share (EPS) of AKER BIOMARINE ASA (AKBM.OL) is expected to grow by 178.44% in the next year.